PATENT CLAIM ANALYSIS

Application Number: 15972472
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2019-03
Patent Classification: ["424", "093700"]

Abstract:
Compositions comprising stem cells delivered into infarcted myocardium by endocardial injection engraft and differentiate into myocytes, endothelial cells, and vascular smooth muscle, and do so without the requirement for survival enhancing modification. These cells engraft whether injected acutely (days) or late (months) after myocardial infarction, and the efficiency of engraftment correlates with the functional recovery of the heart. The stem cells also recruit endogenous cardiac precursor cells, reconstitute myocardial stem cell niches, and enhance endogenous cell differentiation into myocytes.

Claim (Index 45):
The pharmaceutical composition of  claim 44 , wherein the culture media is serum free.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 93.0
- Lexical Diversity: 1.48387
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14473521', '12751445', '15657635', '14940057', '14648621']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7569454575726141
- 35 USC 102 Novelty (BERT): 0.5718382174695604
- Combined Prediction Score: 0.7384347335623087
- Mean Citation Score: 403.806364
- Max Citation Score: 538.00085
- Similarity Product: 316.55143015012743

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test